Investigation of serum level of antituberculous and genetic polymorphism in NAT2 gene in patinet with pulmonary tuberculosis

Investigation of serum level of antituberculous and genetic polymorphism in NAT2 gene in patinet with pulmonary tuberculosis - Investigation of serum level of antituberculous and genetic polymorphism in NAT2 gene in patinet with pulmonary tuberculosis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000006664

Enrollment

Registered

2011-11-03

Start date

2011-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary tuberculosis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The objectives in this investigation is those who fullfil the criterion below. 1) Patinet with active tuberulosis treated with antituberculous drug including rifampicin and isoniazid in Fukushima Medical University 2) Patient who agree written informed consent.

Exclusion criteria

Exclusion criteria: 1) Patinet with drug resistant tuberculosis. 2) Patinet with Human Immunodeficiency virus

Design outcomes

Primary

Measure	Time frame
Duration until acid-fast bacillus sputum examination converts to negative among objective patients.	—

Secondary

Measure	Time frame
The frequency and severity of adverse effects due to anti-tuberculous drugs among objective patinets	—

Countries

Japan

Contacts

Public ContactKengo Oshima

Fukushima Medical University Department of pulmonary medicine

024-547-1360

Outcome results